Real-world efficacy and side effect profile of bempedoic acid in a tertiary centre lipid clinic
Open accessIntegrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In that retrospective analysis, at 12 months mean LDL-C was reduced by 23.3% in the secondary prevention subgroup.
“At 12 months, mean LDL-C was reduced by 25.9% in the overall population (baseline LDL-C = 124 mg/dL) and by 23.3% in the secondary prevention subgroup (baseline LDL-C = 114 mg/dL) compared to baseline [37].”
From Systematic literature review on the real-world effectiveness and safety of bempedoic acid (2026) · cites this paper as [37]
In that retrospective analysis, at 12 months mean LDL-C was reduced by 25.9% in the overall population.
“At 12 months, mean LDL-C was reduced by 25.9% in the overall population (baseline LDL-C = 124 mg/dL) and by 23.3% in the secondary prevention subgroup (baseline LDL-C = 114 mg/dL) compared to baseline [37].”
From Systematic literature review on the real-world effectiveness and safety of bempedoic acid (2026) · cites this paper as [37]
In a retrospective analysis of electronic health records in a mixed prevention cohort, the majority of patients were statin intolerant (86%).
“the majority of patients were statin intolerant (86%) [37].”
From Systematic literature review on the real-world effectiveness and safety of bempedoic acid (2026) · cites this paper as [37]
For that subgroup, achieving the <54 mg/dL target would have required an approximately 53.0% LDL-C reduction from baseline (baseline LDL-C = 114 mg/dL).
“As the baseline LDL-C was 114 mg/dL, achieving this lower LDL-C target would have required an approximately 53.0% LDL-C reduction from baseline [37].”
From Systematic literature review on the real-world effectiveness and safety of bempedoic acid (2026) · cites this paper as [37]
In another small subgroup of patients with ASCVD (n = 20), no patients who received bempedoic acid as monotherapy or the fixed combination with ezetimibe achieved an LDL-C target of <54 mg/dL after 1 year.
“In another small subgroup of patients with ASCVD (n = 20), no patients who received bempedoic acid as monotherapy or the fixed combination with ezetimibe (further details on background LLT not specified) achieved an LDL-C target of <54 mg/dL after 1 year.”
From Systematic literature review on the real-world effectiveness and safety of bempedoic acid (2026) · cites this paper as [37]
LDL-C reductions with bempedoic acid in statin-intolerant patients ranged from 22% to 38%.
“Consistent effects were also seen when bempedoic acid was added to statins (15% to 39%) [25,30,32,38,39,44], and when used in statin intolerant patients (22% to 38%) [24,29,34,35,37,40,41], despite the latter group having higher baseline LDL-C.”
From Systematic literature review on the real-world effectiveness and safety of bempedoic acid (2026) · cites this paper as [37]
Cited by
Sorted by citations
Systematic literature review on the real-world effectiveness and safety of bempedoic acid
Cicero, A. F. G., Cannon, C. P., Gautam, R., Anwar, S., Ghatak, A., Sarnes, E., Powell, H. A., Chhabra, R., & Jawla, S. (2026) · Atherosclerosis Plus · doi:10.1016/j.athplu.2026.100562 · Cited by 1 · see citing works
- Authors
- Moghadam, K. P., David, A., Walji, S., Barton, L., Cegla, J., & Jones, B.
- Affiliations
- Imperial College London (GB)
- Imperial College Healthcare NHS Trust (GB)
- Venue
- Atherosclerosis Plus
- Publisher
- Elsevier BV
- Published
- 2024-09
- Volume
- 57
- Pages
- 9
- ISSN
- 2667-0895 (ISSN-L)
- OpenAlex
- W4403048092
- Cited by
- 0
- References
- 0
- FWCI
- 0.00
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Atherosclerosis Plus (publishedVersion, cc-by-nc-nd)
- Topics
- Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Surgery › Cholesterol and Lipid Metabolism
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Keywords
- bempedoic acid, hypertriglyceridemia, triglyceride-lowering therapy, real-world effectiveness, adverse effects, lipid-lowering drugs
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
